scholarly journals Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5α-Reductase Associated with Benign Prostatic Hypertrophy

Molecules ◽  
2016 ◽  
Vol 21 (7) ◽  
pp. 887 ◽  
Author(s):  
Jun Yin ◽  
Jun Heo ◽  
Yoon Hwang ◽  
Thi Le ◽  
Min Lee
Keyword(s):  
Phenolic Compounds ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Inhibitory Activities

scholarly journals Inhibitory Activities of Dimeric Ellagitannins Isolated from Cornus alba on Benign Prostatic Hypertrophy

Molecules ◽  
2021 ◽  
Vol 26 (11) ◽  
pp. 3446
Author(s):  
Dong-Hui Park ◽  
Kwan-Hee Park ◽  
Jun Yin ◽  
Min-Ji Kim ◽  
Seong-Eun Yoon ◽  
...  
Keyword(s):  
Benign Prostatic Hypertrophy ◽  
Positive Control ◽  
Chronic Inflammatory Disease ◽  
Prostatic Hypertrophy ◽  
Control Group ◽  
Cornus Alba ◽  
Prostate Cells ◽  
Tnf Α ◽  
Proliferation And Apoptosis ◽  
Inhibitory Activities

Benign prostatic hypertrophy (BPH) is an intractable chronic inflammatory disease. We studied the efficacy of two ellagitannins, namely camptothin B (1) and cornusiin A (2) that were isolated from Cornus alba (CA) for the treatment of BPH, which is a common health issue in older men. The ellagitannins (1 and 2) were evaluated on its inhibitory activities of the enzyme 5α-reductase and tumor necrosis factor (TNF)-α, its interleukin (IL)-1β, IL-6, and IL-8 production, and its anti-proliferation and apoptosis induction in prostate cells that show hypertrophy (RWPE-1 cell). In inhibition of 5α-reductase, the ellagitannins (1 and 2) showed potential effects, compared to the positive control, finasteride. In the case of IL-1β, IL-6, IL-8, and TNF-α, 1 and 2 showed good inhibitory effects as compared to the control group treated with LPS. The ellagitannins (1 and 2) were also shown to inhibit proliferation of, and induce apoptosis in, the RWPE-1 cell. These results suggest that the ellagitannins (1 and 2) may be good candidates for the treatment of BPH.

Laser treatment of benign prostatic hypertrophy

1996 ◽  
Vol 63 (1) ◽  
pp. 77-80
Author(s):  
S. Guazzieri ◽  
W. Cecchetti ◽  
M. Meneguolo ◽  
G. D'incà ◽  
R. Bertoldin
Keyword(s):  
Laser Treatment ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Laser Source ◽  
Experimental Procedure ◽  
The Usa ◽  
Side Emission ◽  
Pace Maker ◽  
Stable Laser ◽  
Good Flow

— Laser treatment of benign prostatic hypertrophy (BPH) has gradually become more widespread over the last few years. In the USA it is considered an alternative to endoscopic resection as far as insurance payments are concerned. Different methods are used but the most common and suitable one for urologists is the removal and coagulation of the prostatic tissue under visual control (VLAP or ELAP). The Authors report their personal experience in this type of treatment where good results are due to: 1) combination of a powerful, stable laser source 2) durable side-emission contact fibre 3) laser resector, which also in the absence of epicystostomy maintains a good flow during the operation. However, “laser resection” should still be considered an experimental procedure to be used for randomised protocols or on selected patients (high risk of bleeding, Jehovah's witnesses, carriers of pace-maker, etc.).

SECRETION OF DIHYDROTESTOSTERONE BY HUMAN PROSTATE IN BENIGN PROSTATIC HYPERTROPHY

1974 ◽  
Vol 77 (2) ◽  
pp. 401-407 ◽  
Author(s):  
J. A. Mahoudeau ◽  
A. Delassalle ◽  
H. Bricaire
Keyword(s):  
Plasma Levels ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Human Prostate ◽  
Control Subjects ◽  
Peripheral Plasma ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
And Control

ABSTRACT Plasma levels of testosterone (T) and 5α-dihydrotestosterone (DHT) were determined by radioimmunoassay in 29 patients with benign prostatic hypertrophy (BPH) and in 56 control men of various ages. No significant difference was found in T, DHT nor DHT/T ratio between BPH and control subjects of similar age. Plasma DHT was higher in the prostatic than in the peripheral veins in 8/9 patients with BPH during laparotomy, indicating a prostatic secretion of DHT. No difference in the mean T nor the mean DHT was found in peripheral plasma before and after adenomectomy.

Urogastrone–epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy

1986 ◽  
Vol 70 (4) ◽  
pp. 359-363 ◽  
Author(s):  
H. Gregory ◽  
I. R. Willshire ◽  
J. P. Kavanagh ◽  
N. J. Blacklock ◽  
S. Chowdury ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Seminal Fluid ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Prostatic Fluid ◽  
Show Evidence ◽  
Epidermal Growth ◽  
High Concentrations ◽  
Normal Males

1. High concentrations (272 ± 33 ng/ml) of urogastrone-epidermal growth factor were measured in prostatic fluid from normal males by a specific radioimmunoassay. 2. Significantly lower concentrations (155 ± 24 ng/ml) were observed in the prostatic fluid of patients with benign prostatic hypertrophy than in the age-matched normal controls (2P < 0.01). 3. The growth factor content of seminal fluid was accounted for by the contribution of prostatic fluid. 4. Immunochemical studies failed to show evidence of synthesis within the gland nor could high affinity receptors for the protein be demonstrated in membrane preparations of the gland.

Sign in / Sign up

Export Citation Format

Share Document